US Supreme Court to Consider Sandoz vs Amgen Biosimilar Patent Dance Case on April 26
Rituximab Biosimilar Estimated to Save €90 Million Annually in the EU
Patients' Reluctance to Accept Biosimilars Suggests Need for Better Communication, Education
Nebraska Legislature Debates Biosimilar Substitution Bill
Patent Infringement Litigation: How Early Can It Begin?
In a Surprise Decision, FDA Further Delays Approval of Lilly's RA Drug
Prescribers in England Turn to Biosimilar Growth Hormones for Ease of Use, Not Cost
Senate Bill Seeks to Improve Access to Affordable Rx Drugs
Humira Not Cost Effective for RA, ICER Report Concludes
Study Evaluates Budget Impact of Filgrastim and Similar Biologics for Treating Neutropenia
Sandoz Brief Addresses US Supreme Court in Case Against Amgen
Multiple Challenges Predicted for Biosimilars in 2017
European Drug Agency's Move Out of London, Spurred By Brexit, Could Disrupt Pipeline
Nominee for FDA Commissioner Vows to Strike Balance Before Senate Panel
Biologics Superior for Relief of IBD Symptoms and Maintenance of Intestinal Health
New Research Compares Effectiveness, Safety of Branded and Biosimilar Filgrastim
Indian Generic Pharma Companies in a Race to Develop Biosimilars
MS Drugs Price Comparison Called "Misleading and Oversimplified"
Rituxan Given Breakthrough Therapy Designation for Pemphigus Vulgaris
New Drug Approved for MS, First With PPMS Indication
Infographic: A Guide to Briefs in the Amgen vs Sandoz Supreme Court Case
Dupilumab, a Biologic Treatment for Eczema, Approved by FDA
NHS May Use More "Stick" Than "Carrot" to Ensure Prescribing of Cheaper Biosimilars
Policy Briefing Calls for More Efficient Biosimilar Approval Process
Amgen Gains EC Approval for Biosimilar to Adalimumab
Payer Cost Savings From Filgrastim Biosimilars Could Reach $2 Million Annually
New Lawsuit Concerning Insulin Price-Fixing Filed in Federal Court
Amgen Files for EU Approval of Its Herceptin Biosimilar for Breast Cancer
Infographic: Biosimilar Substitution Laws By State
Congressional Hearing on FDA User Fees Tackles Issues Affecting Biosimilar Approvals
